Ten years of marketing approvals of anticancer drugs in Europe: regulatory policy and guidance documents need to find a balance between different pressures.
about
Trastuzumab-containing regimens for metastatic breast cancerTrastuzumab containing regimens for early breast cancerTrastuzumab containing regimens for early breast cancerTrastuzumab containing regimens for metastatic breast cancerDrug waste minimisation and cost-containment in Medical Oncology: two-year results of a feasibility study.Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers.Surrogate endpoints for overall survival in digestive oncology trials: which candidates? A questionnaires survey among clinicians and methodologistsDoes the development of new medicinal products in the European Union address global and regional health concerns?How can we regulate medicines better?Postmarket safety of drugs approved by Health Canada on the basis of clinical and surrogate outcomes: a cohort study.Oncology drug development and approval of systemic anticancer therapy by the U.S. Food and Drug AdministrationThe financing of drug trials by pharmaceutical companies and its consequences. Part 1: a qualitative, systematic review of the literature on possible influences on the findings, protocols, and quality of drug trials.Patient-reported outcomes in support of oncology product labeling claims: regulatory context and challenges.Literature review on the structure and operation of Pharmacy and Therapeutics Committees.Market access of cancer drugs in European countries: improving resource allocation.Selection of new health technologies for assessment aimed at informing decision making: A survey among horizon scanning systems.Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13.Patients not patents: Drug research and development as a public enterprise.Do no harm: Balancing the costs and benefits of patient outcomes in health psychology research and practice.Predictors for reimbursement of oncology drugs in Belgium between 2002 and 2013.Desperately seeking cancer drugs: explaining the emergence and outcomes of accelerated pharmaceutical regulation.
P2860
Q24194019-6A94ECAD-D428-43A1-BA8E-1CCA95F96CC2Q24200192-6CE1343B-093A-4F35-86A5-F5A7B06F378DQ24244420-13223538-9B3F-46B4-801B-FADB56DA85F8Q24244565-B916584E-7ABF-4CB2-963C-1F15694FB392Q33326482-A4B26DC1-C3F5-4436-899C-4F6B0691C584Q33596863-04663B72-5E74-43D2-A857-6881CDA16FAAQ33600372-50FD5FD6-B6C3-45B8-92C6-D590CA2F0285Q34471198-7DBE4DB6-DC82-452E-B94B-40939740F1B6Q36083448-90E5CE0C-6586-4403-A32A-8FBA370A35D3Q36121661-B0B0CFFB-1F11-4A42-BE8C-4F7E32944A10Q36565598-8A104E3C-DF3C-4C6A-9564-645600CCDC56Q37751910-979AC833-86C9-4D37-90E1-467007D8F479Q37780539-ED1A4919-7CCB-4944-8C66-791167D67A20Q37854531-93D2EF07-6611-4E4B-AB02-89D64FF4000CQ38163486-7839CC84-64AF-4B52-AA9E-1650C12B08C3Q40338614-A09CD4E2-CBCC-4DF3-99F9-AECE760CCB4FQ42281334-6E1CCCFE-FD09-43F1-B5BD-BB1C63547B20Q48112945-5E7F9668-FA7B-4A02-A0E1-0E677F31D9B3Q50206372-E75D8345-1D6D-4222-9312-BABC7E56364CQ50918560-D8458FB9-2EE5-45F4-B1FA-3F38B45D4B22Q53080467-94E47C06-13E9-4CD0-8221-45B3E10B7C4F
P2860
Ten years of marketing approvals of anticancer drugs in Europe: regulatory policy and guidance documents need to find a balance between different pressures.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Ten years of marketing approva ...... e between different pressures.
@ast
Ten years of marketing approva ...... e between different pressures.
@en
type
label
Ten years of marketing approva ...... e between different pressures.
@ast
Ten years of marketing approva ...... e between different pressures.
@en
prefLabel
Ten years of marketing approva ...... e between different pressures.
@ast
Ten years of marketing approva ...... e between different pressures.
@en
P2093
P2860
P356
P1476
Ten years of marketing approva ...... e between different pressures.
@en
P2093
P2860
P2888
P304
P356
10.1038/SJ.BJC.6602750
P407
P577
2005-09-01T00:00:00Z